Moolec Science's Transformative Expansion into Biotech And Pharmaceuticals
St. Louis, Monday, 21 April 2025.
Moolec Science announced a major acquisition to expand its biotech capabilities, capturing over 800 patents and $500M in annual sales across 50 countries. The deal signals a strategic growth shift.
Overview of the Strategic Merger
Moolec Science SA (NASDAQ:MLEC), a key player in the field of molecular farming, has announced a major transformative transaction with Bioceres Group, Nutrecon LLC, and Gentle Technologies Corp. The deal, disclosed on April 21, 2025, involves Moolec issuing up to 87 million shares and 5 million warrants, effectively enhancing its technological reach across multiple platforms and markets [1]. As part of this strategic expansion, Moolec will take the helm of a combined entity that commands over 800 patents and product registrations, with an impressive sales capacity exceeding $500 million annually, spanning operations in over 50 countries [2].
Details of the Transaction
The acquisition, formally initiated through a Business Combination Agreement (BCA) signed on April 17, 2025, signifies a pivotal shift for Moolec, positioning the company as a leader in agricultural technology [1]. In this all-stock transaction, the shareholders of Nutrecon and Gentle Technologies will exchange their equity for newly issued shares of Moolec, marking a defining moment in Moolec’s growth trajectory. The merger is supported by an extraordinary 70% shareholder backing, despite the significant dilution expected from the new share issuance [3].
Strategic Implications and Industry Impact
This merger underscores Moolec’s commitment to leading innovations in molecular farming and biological inputs. By integrating Bioceres Group’s climate-resilient seed technologies and other state-of-the-art R&D capabilities, Moolec is set to redefine sustainable agricultural practices [2]. Key industry figures have praised the merger as a groundbreaking step towards enhancing productivity and sustainability within the biotech sector. Federico Trucco, CEO of Bioceres Crop Solutions Corp, emphasized the role of molecular farming in addressing future agricultural challenges, which this merger exemplifies [4].
Outlook and Future Prospects
Following the expected closure of this transformational transaction in Q2 2025, contingent upon customary regulatory approvals and the completion of Moolec’s reverse stock split process, the newly enlarged entity will continue to develop flagship molecular farming products like Piggy Sooy™ and GLASO™. This presents a robust pathway for advancing Moolec’s technological and market leadership. Furthermore, the company plans to launch pivotal new products by the third quarter of 2025, focusing on emerging markets and technological niches [5].